Intraperitoneal Chemotherapy
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
Frontiers in Oncology 2021 June 18 [Link] Louis Gros, Petr Szturz, Antonella Diciolla, Volker Kirchner, Solange Peters, Niklaus Schaefer, Martin Hubner, Antonia Digklia Abstract Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive…
Read MoreCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up
International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…
Read MoreFeasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases
World Journal of Surgical Oncology 2021 June 5 [Link] Suryanarayana Deo, Mukurdipi Ray, Babul Bansal, Sandeep Bhoriwal, Sushma Bhatnagar, Rakesh Garg, Nishkarsh Gupta, Atul Sharma, Lalit Kumar, Sanjay Thulkar, Ekta Dhamija, Sandeep Mathur, Prasenjit Das Abstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has recently emerged as a viable management option for peritoneal…
Read MoreComplete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy
Techniques in Coloproctology 2020 October [Link] A Arjona-Sánchez, D Cortés-Guiral, M Duran-Martínez, P Villarejo-Campos, J M Sánchez-Hidalgo, A Casado-Adam, L Rodriguez-Ortiz, A Romero-Ruiz, B Rufian-Andujar, E Espinosa-Redondo, F Valenzuela-Molina, S Rufián-Peña, J Briceño-Delgado Abstract Background: The aim of our study was to present the technique for, and early results of complete laparoscopic pelvic peritonectomy (LPP)…
Read MoreUnusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series
Surgical Oncology 2020 June [Link] Paul H Sugarbaker, O Anthony Stuart Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Methods:…
Read MoreOutcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BJS Open 2021 March 5 [Link] A Zahid, L Clarke, N Carr, K Chandrakumaran, A Tzivanakis, S Dayal, F Mohamed, T Cecil, B J Moran Abstract Background: Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, generally considered a borderline malignancy, best treated by cytoreductive surgery (CRS) to remove macroscopic disease, combined with hyperthermic intraperitoneal chemotherapy…
Read MoreClinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy
Therapeutic Advances in Urology 2020 December 10 [Link] Özgül Düzgün, Murat Kalın, Resul Sobay, Ömer Faruk Özkan Abstract Background: Urinary system resections and reconstructions are needed in peritoneal carcinomatosis due to abdominal malignancies. The effect of hyperthermic intraperitoneal chemotherapy on these urological procedures after reconstruction remains uncertain. The aim of the study is to evaluate…
Read MoreHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
British Journal of Cancer 2020 October 26 [Link] Michael G White, Jefree J Schulte, Lai Xue, Yaniv Berger, Darryl Schuitevoerder, Charles C Vining, Hedy L Kindler, Aliya Husain, Kiran K Turaga, Oliver S Eng Abstract Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune…
Read MoreMulticystic peritoneal mesothelioma treated with complete cytoreductive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy-A case report
International Journal of Surgery Case Reports 2020 [Link] Naveen Padmanabhan, Haruaki Ishibashi, Kazurou Nishihara, Shouzou Sako, Kanji Katayama, Satoshi Wakama, Yasuyuki Kamada, Yutaka Yonemura Abstract Background: Multicystic Peritoneal mesothelioma is a rare and distinct variety of peritoneal mesothelioma with borderline malignant potential. Conventional Tumor bulking has been associated with recurrence of 45-50 %. Hence a…
Read MoreAdvances with pharmacotherapy for peritoneal metastasis
Expert Opinion on Pharmacotherapy 2020 August 12 [Link] Yutaka Yonemura, Haruaki Iahibashi, Shouzou Sako, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Shunsuke Motoi, Yang Liu, Satoshi Wakama, Yasuyuki Kamada, Kazurou Nishihara Abstract Introduction: A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology…
Read More